Long COVID neurofunctional sequelae are emerging as a major challenge for global healthcare systems. Recent evidence suggests that psychomotor and neurofunctional impairments can persist for at least 24 weeks after the initial SARS-CoV-2 infection. Consequently, medical professionals must remain vigilant in screening recovered patients for these subtle but debilitating deficits. Early detection and tailored rehabilitation strategies are essential to improve patient quality of life.

A comprehensive longitudinal study assessed patients using eight psychomotor tests and cognitive tasks from the Mini-Mental State Examination. The researchers discovered that psychomotor deficits were particularly pronounced and persistent in the 31–45-year age group. In contrast, memory-related impairments appeared more evident in younger adults aged 18–30. Furthermore, the presence of body pain, coryza, and sore throat during the acute phase served as strong predictors of long-term sequelae. Interestingly, Rh-negative blood type was identified as a potential biological risk factor for these persistent conditions.

Addressing Long COVID Neurofunctional Sequelae in Clinical Practice

In the Indian context, the burden of Neuro-PASC (Post-Acute Sequelae of SARS-CoV-2) is substantial. For instance, a multi-site study including participants from Jaipur revealed that nearly 70% of long COVID patients experienced at least one neurological symptom. These symptoms ranged from brain fog and dizziness to severe cognitive slowing. Moreover, research from Indian cohorts emphasizes that subjective recovery often masks measurable deficits in working memory and executive function. Therefore, practitioners should prioritize objective neurofunctional assessments over patient self-reporting during follow-up visits.

Management of these sequelae requires a multidisciplinary approach involving neurologists, psychiatrists, and primary care physicians. Additionally, clinicians should educate patients about the possibility of "premature senescence" or accelerated biological aging linked to severe infections. Similarly, lifestyle interventions and targeted cognitive exercises may support neuroplasticity and recovery. As the global understanding of the virus evolves, continuous monitoring remains the cornerstone of effective long-term care.

Frequently Asked Questions

What are the primary symptoms of long COVID neurofunctional sequelae?

The primary symptoms include psychomotor impairments like reduced balance and coordination, alongside cognitive issues such as brain fog, memory loss, and reduced verbal fluency. Physical symptoms like persistent body pain are also frequently associated with these deficits.

Which age group is most affected by these impairments?

Research indicates that psychomotor impairments are most pronounced in individuals aged 31–45. However, memory-related issues are more frequently observed in the younger 18–30 age group, suggesting that the virus affects the central nervous system differently across the lifespan.

Can specific blood types increase the risk of neurological sequelae?

Preliminary findings suggest that individuals with Rh-negative blood types might have a higher susceptibility to long-term neurofunctional impairments. However, further large-scale genomic studies are required to confirm this biological association.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Chiminazzo LLW et al. Psychomotor and neurofunctional sequelae after COVID-19. Acta Neuropsychiatr. 2026 Mar 05. doi: 10.1017/neu.2026.10067. PMID: 41784006.

Singh et al. Neuropsychiatric manifestations of Long COVID in India: a persistent problem 2.5 years after disease onset. PubMed. 2025 Nov 12.

IIIT Hyderabad. Long-term Impact of COVID-19 on Cognition and Mental Health in an Indian Cohort. medRxiv. 2025 Nov 18.